RadioPharm Theranostics Hits 50% Enrollment Milestone in RAD101 Imaging Study

RadioPharm Theranostics has reached 50% enrollment in its Phase 2b trial for imaging brain metastases with RAD101, a novel imaging small molecule targeting fatty acid synthase. The trial aims to demonstrate RAD101's potential to distinguish true tumor recurrence from radiation necrosis. The company expects to complete the trial and report topline results in the first half of 2026.